Sequenom, Inc (NASDAQ:SQNM) rose by 6.90% on Friday


Dallas, Texas 11/18/2013 (Financialstrend) – In Friday’s trading session, Sequenom, Inc (NASDAQ:SQNM) rose by 6.90%. The shares opened at a price of $2.31, which touched the intraday high of $2.51 and headed to a close of $2.48. Around 3.03 million exchanged hands over the trading day and an average volume of 3.85 million shares were traded over a 30 day period. The 52-week low of Sequenom, Inc (NASDAQ:SQNM) shares is $1.65 and its 52-week high is $5.36. Sequenom, Inc (NASDAQ:SQNM) has a market capitalization of $286.98 million.                                        

About the company

Sequenom, Inc (NASDAQ:SQNM) was formed in 1994. It is a molecular-diagnostic testing & genetics-analysis company that is committed to providing molecular-diagnostic testing services & research-use only services. In addition to this, Sequenom, Inc (NASDAQ:SQNM) has products, applications & genetic-analysis products that translate results of genomic- science into solutions that are used in biomedical research, translational-research, molecular medicine applications & livestock, agricultural & other research areas.

Sequenom, Inc (NASDAQ:SQNM)’s development & commercialization- efforts in different  diagnostic areas include the noninvasive women’s-health-related & prenatal diagnostics, ophthalmology & other medical-conditions, like oncology, infectious-diseases & autoimmunity. Sequenom, Inc (NASDAQ:SQNM) operates in 2 business segments: Molecular Diagnostics. This includes its Sequenom Center for Molecular-Medicine, LLC/ Sequenom CMM) & Genetic Analysis. In 2011 November, Sequenom, Inc (NASDAQ:SQNM) entered into leases for additional-laboratory & office-space in California, San Diego and Durham, North Carolina.

Molecular Diagnostics

Sequenom, Inc (NASDAQ:SQNM) is involved in researching & developing & pursuing commercialization of different  noninvasive molecular-diagnostic tests for prenatal-genetic disorders & diseases, women’s-health-related disorders & diseases, ophthalmology & other medical-conditions like infectious diseases oncology & autoimmunity. As of 31 December 2011, Sequenom, Inc (NASDAQ:SQNM) is mainly focused on developing & commercializing prenatal-diagnostic tests. All these test use the company’s patent-protected, foundational, non-invasive, circulating cell-free fetal , nucleic-acid-based assay technology, which Sequenom, Inc (NASDAQ:SQNM) had in-licensed from the Isis Innovation Limited.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.